WHO ICTRP trial
Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary…
EUCTR2005-005602-23-EE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2005-005602-23-EE |
|---|---|
| Public title | Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease (COPD) in a Randomized, Double-Blind, Placebo-Controlled Study of Treatment with Fluticasone Propionate/Salmeterol 500/50mcg combination (FSC 500/50) and its individual components, Fluticasone Propionate 500mcg (FP500) and Salmeterol 50mcg (SAL 50) |
| Scientific title | Evaluation of Novel Endpoints in Subjects with Chronic Obstructive Pulmonary Disease (COPD) in a Randomized, Double-Blind, Placebo-Controlled Study of Treatment with Fluticasone Propionate/Salmeterol 500/50mcg combination (FSC 500/50) and its individual components, Fluticasone Propionate 500mcg… |
| Primary sponsor | GlaxoSmithKline Research & Development |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Estonia |
| Conditions | Chronic Obstructive Pulmonary Disease (COPD) |
| Interventions | Trade Name: Seretide Diskus 50/500mcg/dose Product Name: fluticasone propionate/ salmeterol 500/50mcg combination Product Code: FSC 500/50 Pharmaceutical Form: Inhalation powder, pre-dispensed INN or Proposed INN: Salmeterol xinafoate CAS… |
| Registration date | Jan 26, 2006 |
| Target size | 140 |
| Secondary IDs | SCO104925 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: